FDA Makes Statement on Naproxen (Aleve)
Related MedicineNet Links
- naproxen, Naprosyn, Naprelan, Anaprox, Aleve (information on this OTC drug)
- Nonsteroidal Antiinflammatory Drugs (NSAIDs) (information on this class of drug)
- Chronic Pain (article)
- Medications Channel
FDA Statement on Naproxen
The FDA today released the following statement on NIH halting a clinical trial involving non-steroidal anti-inflammatory drugs in patients at risk of developing Alzheimer's Disease:
The Food and Drug Administration (FDA) is working with the National Institutes of Health to review the available scientific information on naproxen following the decision of the National Institute on Aging to halt a clinical trial studying non-steroidal anti-inflammatory drugs in patients at risk of developing Alzheimer's disease. Preliminary information from the study showed some evidence of increased risk of cardiovascular events, when compared to placebo, to patients taking naproxen.
In the meantime, FDA advises patients who are currently taking over-the-counter naproxen products to carefully follow the instructions on the label. Patients should not exceed the recommended doses for naproxen (220 milligrams twice daily) and should not take naproxen for longer than ten days unless a physician directs otherwise. Patients with questions about naproxen should consult their physicians.
Source: FDA Statement, December 20, 2004
Daily Health News
Subscribe to MedicineNet's General Health Newsletter